Today's Top Biotech Stocks to Watch: Geron Corporation and Arena Pharmaceuticals

Today's top health care and biotech stocks.

Jun 12, 2014 at 8:26AM


Let's take a look at today's top stories in biotech and health care. Keep an eye out for Geron Corporation (NASDAQ:GERN) and Arena Pharmaceuticals (NASDAQ:ARNA)

Geron is soaring this morning on clinical update
Shares of clinical-stage biotech Geron are up over 30% in premarket this morning after the company announced that a partial clinical hold for its experimental myelofibrosis treatment called imetelstat has been lifted by the Food and Drug Administration. In March, the FDA placed a clinical hold on imetelstat after patients receiving the treatment exhibited signals for an increased risk of liver toxicity. Dr. Ayalew Tefferi of the Mayo Clinic has been providing additional safety data to the FDA since the hold was put into place, leading to today's partial release.

What's key to understand is that the FDA still has a clinical hold on imetelstat as a treatment for essential thrombocythemia and multiple myeloma. Moreover, Geron cannot initiate new clinical trials with the drug until the full hold is released.

I think today's news is a step in the right direction, but it remains to be seen if the FDA will release the hold for these other indications. It's also important to understand that the required laboratory studies will take some time to complete, so you shouldn't expect the full hold to be lifted anytime soon. As such, investors with a long term outlook might want to stay on the sidelines for the time being, especially since the bulk of Geron's value is directly tied to imetelstat.      

Arena could be in for a big day
Shares of anti-obesity pill maker Arena Pharmaceuticals gained over 4% in after hours trading yesterday following an interview with CEO Jack Lief on CNBC. Investors are apparently intrigued by his comments about a recent uptick in Belviq prescriptions, as well as his lack of commentary regarding a possible buyout by marketing partner Eisai. Adding fuel to the fire, Orexigen's competing drug Contrave had its regulatory review extended by three months yesterday, giving Belviq at least another quarter before it will face increased competition. 

While improving Belviq sales and a regulatory delay for a competing drug are good fundamental reasons to dig deeper in this mid-cap biotech, I think the buyout rumor simply doesn't have legs for a couple of reasons. We've heard this same rumor multiple times since Belviq's approval, and it has never panned out. And Belviq's sales as a treatment for chronic obesity have been lackluster, giving Eisai (in my opinion) little reason to make an offer. In sum, you should focus on Arena's underlying business -- and not potential buyout rumors -- when considering an investment. 

Leaked: A huge small-cap opportunity
This smart device –kept secret until now – could mark a new revolution in smart tech (with big implications for health care). It’s a gigantic market opportunity -- ABI Research predicts 485 million of its type will be sold per year. To learn about the small-cap stock making this device possible – the stock that could mint millionaires left and right when its full market potential is realized – click here.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information